Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of FL058 in Healthy Chinese Subjects
NCT05058118Phase 1Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Dec 2019
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Gram-negative bacterial infection comparing FL058 (Pralurbactam) with Placebo (2 arms). Primary endpoint: Number of patients with adverse events. Started Dec 2019; status: completed.
02
Drugs
pralubactam
03
Conditions
Gram-negative bacterial infection
Beyond the preview
Go deeper on NCT05058118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05058118.